ES2151652T3 - Derivados de indol como antagonistas del receptor 5ht. - Google Patents

Derivados de indol como antagonistas del receptor 5ht.

Info

Publication number
ES2151652T3
ES2151652T3 ES96902259T ES96902259T ES2151652T3 ES 2151652 T3 ES2151652 T3 ES 2151652T3 ES 96902259 T ES96902259 T ES 96902259T ES 96902259 T ES96902259 T ES 96902259T ES 2151652 T3 ES2151652 T3 ES 2151652T3
Authority
ES
Spain
Prior art keywords
indol
antagonists
derivatives
receiver
employment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96902259T
Other languages
English (en)
Inventor
Laramie M Gaster
Paul A Wyman
Keith R Mulholland
David T Davies
David M Duckworth
Ian T Forbes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9502052.5A external-priority patent/GB9502052D0/en
Priority claimed from GBGB9508327.5A external-priority patent/GB9508327D0/en
Priority claimed from GBGB9508967.8A external-priority patent/GB9508967D0/en
Priority claimed from GBGB9516845.6A external-priority patent/GB9516845D0/en
Priority claimed from GBGB9517542.8A external-priority patent/GB9517542D0/en
Priority claimed from GBGB9518574.0A external-priority patent/GB9518574D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2151652T3 publication Critical patent/ES2151652T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

LA INVENCION SE REFIERE A COMPUESTOS HETEROCICLICOS CON ACTIVIDAD FARMACOLOGICA, A LOS PROCESOS PARA SU PREPARACION, A LAS COMPOSICIONES QUE LOS CONTIENEN Y A SU EMPLEO EN EL TRATAMIENTO DE TRASTORNOS DEL SNC COMO LA ANSIEDAD.
ES96902259T 1995-02-02 1996-01-26 Derivados de indol como antagonistas del receptor 5ht. Expired - Lifetime ES2151652T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9502052.5A GB9502052D0 (en) 1995-02-02 1995-02-02 Novel compounds
GBGB9508327.5A GB9508327D0 (en) 1995-04-25 1995-04-25 Novel compounds
GBGB9508967.8A GB9508967D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9516845.6A GB9516845D0 (en) 1995-08-17 1995-08-17 Novel compounds
GBGB9517542.8A GB9517542D0 (en) 1995-08-26 1995-08-26 Novel compounds
GBGB9518574.0A GB9518574D0 (en) 1995-09-12 1995-09-12 Novel compounds
PCT/EP1996/000368 WO1996023783A1 (en) 1995-02-02 1996-01-26 Indole derivatives as 5-ht receptor antagonist

Publications (1)

Publication Number Publication Date
ES2151652T3 true ES2151652T3 (es) 2001-01-01

Family

ID=27547235

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96902259T Expired - Lifetime ES2151652T3 (es) 1995-02-02 1996-01-26 Derivados de indol como antagonistas del receptor 5ht.

Country Status (34)

Country Link
US (3) US5990133A (es)
EP (1) EP0808312B1 (es)
JP (1) JPH10513442A (es)
KR (1) KR19980701879A (es)
CN (1) CN1151147C (es)
AP (1) AP657A (es)
AR (1) AR002705A1 (es)
AT (1) ATE197300T1 (es)
AU (1) AU699727B2 (es)
BG (1) BG101806A (es)
BR (1) BR9607016A (es)
CA (1) CA2212061A1 (es)
CZ (1) CZ294097B6 (es)
DE (1) DE69610822T2 (es)
DK (1) DK0808312T3 (es)
EA (1) EA000304B1 (es)
ES (1) ES2151652T3 (es)
FI (1) FI973205A (es)
GR (1) GR3035075T3 (es)
HK (1) HK1003883A1 (es)
HU (1) HU223601B1 (es)
IL (1) IL116998A (es)
MA (1) MA23792A1 (es)
MY (1) MY132229A (es)
NO (1) NO313520B1 (es)
NZ (1) NZ301265A (es)
OA (1) OA10502A (es)
PL (1) PL184490B1 (es)
PT (1) PT808312E (es)
RO (1) RO115522B1 (es)
SI (1) SI0808312T1 (es)
SK (1) SK103897A3 (es)
TR (1) TR199700749T1 (es)
WO (1) WO1996023783A1 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212061A1 (en) * 1995-02-02 1996-08-08 Laramie Mary Gaster Indole derivatives as 5-ht receptor antagonist
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9612885D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6420541B1 (en) 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6541209B1 (en) 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9710523D0 (en) * 1997-05-23 1997-07-16 Smithkline Beecham Plc Novel compounds
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO1999043650A2 (en) * 1998-02-25 1999-09-02 Smithkline Beecham Plc Process(es) for the preparation of 6-trifluoromethyl-indoline derivatives
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2378243C (en) * 1999-08-04 2012-05-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
EP1264820A4 (en) * 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
US6448293B1 (en) 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
FR2807754A1 (fr) * 2000-04-13 2001-10-19 Adir Nouveaux derives de cyclobuta-indole carboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US6610747B2 (en) 2000-08-31 2003-08-26 Pfizer Inc. Phenoxybenzylamine derivatives as SSRIs
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
GB2380190A (en) * 2001-08-28 2003-04-02 Bayer Ag Antiinflammatory heterocyclic sulphones
EP1895684B1 (en) 2001-09-29 2012-05-16 LG Electronics, Inc. Method for transferring and/or receiving data in communication system and apparatus thereof
KR20050044417A (ko) 2001-11-14 2005-05-12 쉐링 코포레이션 카나비노이드 수용체 리간드
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
US20050130977A1 (en) 2002-04-08 2005-06-16 Lindsley Craig W. Inhibitors of akt activity
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
JP2005533809A (ja) 2002-06-19 2005-11-10 シェーリング　コーポレイション カンナビノイドレセプタアゴニスト
EP1545523A1 (en) * 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
KR20050033653A (ko) * 2002-08-23 2005-04-12 리겔 파마슈티칼스, 인크. Ｈｃｖ 감염의 치료 또는 예방에 유용한 피리딜 치환 헤테로사이클
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
DE60336576D1 (de) 2002-10-30 2011-05-12 Merck Sharp & Dohme Hemmer der akt aktivität
CA2511178A1 (en) * 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2004058683A2 (en) * 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004096130A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
EA009732B1 (ru) 2003-07-22 2008-02-28 Арена Фармасьютикалз, Инк. Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
CN1926114B (zh) * 2004-03-23 2011-08-24 艾尼纳制药公司 用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
EP1789390B1 (en) * 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN101160127A (zh) * 2005-01-19 2008-04-09 艾尼纳制药公司 用于预防或治疗进行性多灶性白质脑病而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
CA2620818A1 (en) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
EP2202222A3 (en) 2005-11-08 2010-09-15 Laboratorios Del Dr. Esteve, S.A. Indene derivatives, their preparation and use as medicaments
EP2018371B1 (en) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
EP3395816A1 (en) 2006-05-18 2018-10-31 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US20080182837A1 (en) * 2006-07-07 2008-07-31 Steffen Steurer New chemical compounds
EP1884515A1 (en) 2006-07-31 2008-02-06 Laboratorios del Dr. Esteve S.A. Substituted indanyl sulfonamide compounds, their preparation and use as medicaments
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
LT2848610T (lt) * 2006-11-15 2017-11-10 Ym Biosciences Australia Pty Ltd Kinazės aktyvumo inhibitoriai
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
EP2155643B1 (en) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a inhibitors
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
EP2176249A2 (en) * 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH New chemical compounds
DE602007012683D1 (de) 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010034838A2 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9034911B2 (en) 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
CN102348798A (zh) 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
US8598345B2 (en) * 2009-09-17 2013-12-03 Vanderbilt University Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US9751847B2 (en) 2010-10-14 2017-09-05 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
PL2762466T3 (pl) * 2011-09-29 2017-09-29 Ono Pharmaceutical Co., Ltd. Pochodna fenylu
EP2763532B1 (en) 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6307096B2 (ja) 2013-01-23 2018-04-04 アストラゼネカ アクチボラグ 化合物
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
EP3419980A4 (en) 2016-02-26 2019-07-03 The Board of Trustees of the Leland Stanford Junior University INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
WO2019032528A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc BICYCLIC HISTONE DEACETYLASE INHIBITORS
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
WO2023114313A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
WO2023114320A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Fused pyrrolidine psychoplastogens and uses thereof
WO2023114325A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Constrained amine psychoplastogens and uses thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL126227C (es) * 1958-08-22
SE370866B (es) * 1968-03-21 1974-11-04 Ciba Geigy Ag
CA2091246A1 (en) * 1990-09-13 1992-03-14 Ian Thomson Forbes Indole ureas as 5 ht receptor antagonist
CA2142721A1 (en) * 1992-08-20 1994-03-03 Ian T. Forbes Condensed indole derivatives as 5ht and 5ht antagonists
GB9306460D0 (en) * 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
CA2212061A1 (en) * 1995-02-02 1996-08-08 Laramie Mary Gaster Indole derivatives as 5-ht receptor antagonist

Also Published As

Publication number Publication date
HU223601B1 (hu) 2004-10-28
RO115522B1 (ro) 2000-03-30
US20030105139A1 (en) 2003-06-05
FI973205A (fi) 1997-10-01
AU699727B2 (en) 1998-12-10
JPH10513442A (ja) 1998-12-22
SI0808312T1 (es) 2001-02-28
US6638953B2 (en) 2003-10-28
DE69610822T2 (de) 2001-06-07
AU4664696A (en) 1996-08-21
CZ294097B6 (cs) 2004-10-13
EP0808312B1 (en) 2000-11-02
DK0808312T3 (da) 2001-02-12
NO973543L (no) 1997-10-01
HK1003883A1 (en) 1998-11-13
EA000304B1 (ru) 1999-04-29
FI973205A0 (fi) 1997-08-01
ATE197300T1 (de) 2000-11-15
NO313520B1 (no) 2002-10-14
CN1179156A (zh) 1998-04-15
WO1996023783A1 (en) 1996-08-08
IL116998A0 (en) 1996-09-12
HUP9901115A3 (en) 2000-02-28
NZ301265A (en) 1998-12-23
NO973543D0 (no) 1997-08-01
AP657A (en) 1998-08-06
AR002705A1 (es) 1998-04-29
CZ244597A3 (cs) 1998-09-16
PL184490B1 (pl) 2002-11-29
US5990133A (en) 1999-11-23
AP9701036A0 (en) 1997-07-31
HUP9901115A2 (hu) 1999-07-28
OA10502A (en) 2002-04-12
GR3035075T3 (en) 2001-03-30
PT808312E (pt) 2001-03-30
CN1151147C (zh) 2004-05-26
KR19980701879A (ko) 1998-06-25
SK103897A3 (en) 1998-02-04
EP0808312A1 (en) 1997-11-26
CA2212061A1 (en) 1996-08-08
EA199700156A1 (ru) 1997-12-30
BG101806A (en) 1998-04-30
DE69610822D1 (de) 2000-12-07
PL321706A1 (en) 1997-12-22
MA23792A1 (fr) 1996-10-01
TR199700749T1 (xx) 1998-02-21
US6235758B1 (en) 2001-05-22
BR9607016A (pt) 1997-10-28
MY132229A (en) 2007-09-28
IL116998A (en) 2001-08-08

Similar Documents

Publication Publication Date Title
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
MX9302888A (es) 1,2,3,4-tetrahidroisoquinolinas substituidas con propiedades antagonistas del receptor de angiotensina ii.
ES2141913T3 (es) Agonistas y antagonistas de los receptores de la adenosina a1.
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
PA8510001A1 (es) Antagonistas del factor liberador de corticotropina
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
AR029199A1 (es) Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
ES2180798T3 (es) Derivados de pirimidina como antagonistas del receptor de 5ht2c.
ES2134859T3 (es) Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
NO994850L (no) Farmakologiske midler
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
ES2190487T3 (es) Nuevos agonistas y antagonistas del receptor de adenosina a1.
MX9400341A (es) Derivados de los acidos quinolon- y naftiridon-carboxilicos, procedimiento para su obtencion y agentes antibacterianos y aditivos para piensos que los contienen.
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
ES2161718T3 (es) 2,5-dioxo-2,5-dihidro-1h-benzo(b)azepinas como antagonistas de los receptores de nmda.
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
AR024747A1 (es) Derivados de aminotiazoles, su preparacion y las composiciones farmaceuticas que los contienen.
ES2152682T3 (es) Derivados de indolina utiles como antagonistas del receptor 5ht-2c.
AR004129A1 (es) Nuevos agentes glicomimeticos como antagonistas de selectinas y medicamentos que actuan inhibiendo las inflamaciones.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19980601

FG2A Definitive protection

Ref document number: 808312

Country of ref document: ES